Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 20, 2024

Patient-Reported Outcomes of Trastuzumab Deruxtecan Therapy vs Treatment of Physician's Choice in Patients With HER2+ MBC

The Lancet Oncology


Additional Info

The Lancet Oncology
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol 2024 May 01;25(5)614-625, T Fehm, F Cottone, K Dunton, F André, I Krop, YH Park, M De Laurentiis, Y Miyoshi, A Armstrong, MR Borrego, R Yerushalmi, FP Duhoux, T Takano, W Lu, A Egorov, SB Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading